Alemtuzumab effective in treating early MS but associated with autoimmunity
November 1st 2008A phase 2 study published in the New England Journal of Medicine reported that alemtuzumab was more effective than interferon beta-1a in treating early, relapsing-remitting multiple sclerosis (MS), but the agent was also associated with higher rates of autoimmunity, including cases of immune thrombocytopenic purpura (ITP).
Read More
Spotlight on pharmaceutical pipeline database products: A useful resource for PBMs and MCOs
November 1st 2008To effectively gauge the potential clinical and economic impact of drug and biologic therapies that are pending FDA approval, the monitoring of pharmaceutical pipelines has become an essential function of pharmacy benefit management (PBM) companies and managed care organizations (MCOs); one source of pharmaceutical pipeline information is subscription-based pharmaceutical pipeline databases. Examples of some of these databases, along with the types of information provided and advantages and disadvantages of such products, are presented.
Read More
Prasugrel: A novel thienopyridine prodrug for the treatment of acute coronary syndrome
November 1st 2008Prasugrel is a thienopyridine prodrug under FDA review for the treatment of acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI). Clinical trials have demonstrated statistically significant inhibition of platelet aggregation with prasugrel relative to placebo and clopidogrel; however, this improved efficacy outcome entails a significantly increased rate of bleeding.
Read More
Unpredictable market renders past strategies ineffective
November 1st 2008Unfortunately, healthcare's complex business model, dynamic technology and regulatory changes, and potential for market disruptions render conventional strategic planning processes and financial decision-making tools less effective.
Read More
Charter Oak offers affordable access
November 1st 2008The Connecticut Department of Social Services launched Charter Oak Health Plan in June, a subsidized, public-private plan with no income limits and guaranteed issue. It's a suitable fit for the working uninsured, a target segment for other health reform coverage proposals nationwide.
Read More